Market Cap: $505.47B
Market Cap: $505.47B
Open
$259.73
Prev. Close
$292.82
High
$260.92
Low
$253.61
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines.
AbbVie Inc. trades on the New York Stock Exchange under the ticker ABBV, priced in USD.
AbbVie Inc. has a market capitalisation of $505.47B, based on its latest share price.
ABBV trades at 50.56 times its trailing 12-month earnings.
Over the past 52 weeks ABBV has traded between $190.75 and $302.93.
Yes. AbbVie Inc.'s dividend yields 2.35% at the current share price, paying out 117% of its earnings.
Highly profitable: keeps 15.7% of revenue as net profit.
The analyst consensus rating for ABBV is Buy. Analysts' average 12-month price target of $284.18 implies 1% downside.
Robert A. Michael is the CEO of AbbVie Inc., which is headquartered in North Chicago.
Generated automatically from reported financial data. General information only, not financial advice.

AbbVie: Navigating the Post-Humira Landscape AbbVie Inc. ( ABBV ) is strategically evolving as it transitions away from its once-flagship drug, Humira. With the expiration of Humira's patent, the comp…

The Legacy of Humira and Its Decline Humira has played a pivotal role in AbbVie's success, generating billions in revenue from its efficacy in treating autoimmune diseases. However, with the looming p…

AbbVie Inc. ( ABBV ) is navigating a pivotal transformation in the biopharmaceutical landscape, emerging from the shadows of its once-flagship product, Humira. As the patent expired on Humira, which h…

AbbVie Inc. ( ABBV ) is experiencing a remarkable transformation as it adapts to market shifts following the patent expiration of its flagship drug, Humira. Initially, Humira's unparalleled success es…